Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
THT 2024
Start date: Mar 06, 2024 End date: Mar 04, 2024
The CardioVascular Research Foundation (CRF) proudly organizes Technology and Heart Failure Therapeutics (THT) 2024.This conference offers a unique perspective by uniting device- and technology-based therapies with drug-based approaches, effectively bridging gaps in current practices. Attendees can expect comprehensive updates on the status of treatments for heart failure, spanning drug and… View more

Heart Failure
Left Atrium Role in Secondary Mitral Regurgitation
Author(s): Markos Koukos , Yannis Dimitroglou , Dimitrios Tsartsalis , et al Added: 1 year ago

Vascular Disease and Surgery

Imaging & Diagnostics
TCT Connect
TCT Transcatheter Cardiovascular Therapeutics (TCT) is organised by Radcliffe Cardiology partner CardioVascular Research Foundation (CFR).TCT provides physicians opportunities for hands-on training, interactive learning, live case demonstrations, and to network, all with access to world-class KOLs and experts! View more
View from the Thoraxcenter: EuroPCR 25 Late-breaking Preview
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 week ago
Step into the forefront of interventional cardiology with distinguished experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they provide a comprehensive overview of EuroPCR 2025's most anticipated late-breaking trials.Optimize your conference preparation through this essential preview, where expert commentary outlines the clinical significance of this… View more

Intervention
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 3 days ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 23 hours ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
Research Area(s) / Expertise:

Cardio-oncology

 Job title: United Therapeutics Medical Affairs Fellow
Dr SarahKaspari is anUnited Therapeutics Medical Affairs Fellow atUNC Eshelman School of Pharmacy, Chapel Hill, US. View more
AHA 24: The LIBerate-HeFH_OLE Study
Author(s): Frederick Raal Added: 6 months ago
AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).LIBerate-HeFH_OLE is an open… View more

Prevention & Chronic Conditions
Martin Rothman
Job title: Co-founder
Co-Founder of CorFlow Therapeutics AG, Chief Medical Officer and VP of Medical Affairs, Medtronic Coronary, RDN & Structural Heart, Santa Rosa, CA, USA, Honorary Professor of Interventional Cardiology, Queen Mary, University of London, United Kingdom View more